Anti-tumor activity of trimethoprim-sulfamethoxazole against melanoma skin cancer through triggering allergic reaction and promoting immunity
International Immunopharmacology · 2023-10 · 123 · 110742
DOI: 10.1016/j.intimp.2023.110742 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Immunopharmacology, 2023-10. Verfasst von Hee-Yun Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Biochip Research Center, Hoseo University, Asan, Chungnam 31499, Republic of Korea. Hauptthemen laut MEDLINE: Hypersensitivity, Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 64 Literaturangaben. Gefördert von: National Research Foundation of Korea, Ministry of Science, ICT and Future Planning.
Abstract (Originalsprache)
The anti-cancer impact of an allergic reaction is strongly linked to immunity enhancement. Trimethoprim-sulfamethoxazole (TMP-SMX), an antibiotic, has potential immunomodulatory effects, but has side effects such as allergies. Thus far, the effects and underlying mechanisms of TMP-SMX in melanoma have not been clarified. This study examined the potential roles of TMP-SMX in melanoma skin cancer using an immunodeficient mouse model. TMP-SMX significantly improved the survival rate and reduced the tumor weight and growth and vascular endothelial growth factor levels in melanoma skin cancer of immunodeficient mice. In the forced swimming test, TMP-SMX significantly reduced immobility time compared to the melanoma skin cancer of immunodeficient mice, indicating improved immunity. TMP-SMX significantly increased infiltration of mast cells and release of allergy-related mediators (IgE, histamine, interleukin (IL)-4, IL-5, IL-13, and IL-33) and immune-enhancing mediators (tumor necrosis factor-α, IL-2, IL-6, and IL-12). In addition, the administration of TMP-SMX significantly increased the caspase-3, 8, and 9 activities. Furthermore, mice given TMP-SMX showed no adverse reactions according to the blood biochemical parameters. TMP-SMX significantly inhibits the growth of melanoma skin cancer by triggering an allergic reaction and promotingimmunity. Hence, we propose that TMP-SMX may be used as an immune booster in cancer chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biochip Research Center, Hoseo University, Asan, Chungnam 31499, Republic of Korea.
- Department of Bio-Convergence System, Graduate School, Hoseo University, Asan 31499, Republic of Korea.
- Department of Pharmacology, College of Korean Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea.
- Biochip Research Center, Hoseo University, Asan, Chungnam 31499, Republic of Korea; Department of Bio-Convergence System, Graduate School, Hoseo University, Asan 31499, Republic of Korea; Department of Food Science & Te…
Förderung
- National Research Foundation of Korea
- Ministry of Science, ICT and Future Planning
Zitieren
APA
Kim, H. Y., Kang, H. G., Kim, H. M., & Jeong, H. J. (2023). Anti-tumor activity of trimethoprim-sulfamethoxazole against melanoma skin cancer through triggering allergic reaction and promoting immunity. International Immunopharmacology, 123, 110742. https://doi.org/10.1016/j.intimp.2023.110742
Vancouver
Kim HY, Kang HG, Kim HM, Jeong HJ. Anti-tumor activity of trimethoprim-sulfamethoxazole against melanoma skin cancer through triggering allergic reaction and promoting immunity. International Immunopharmacology. 2023;123:110742. doi:10.1016/j.intimp.2023.110742
BibTeX
@article{Kim2023,
author = {Kim, Hee-Yun and Kang, Ho-Geun and Kim, Hyung-Min and Jeong, Hyun-Ja},
title = {Anti-tumor activity of trimethoprim-sulfamethoxazole against melanoma skin cancer through triggering allergic reaction and promoting immunity},
journal = {International Immunopharmacology},
year = {2023},
volume = {123},
pages = {110742},
doi = {10.1016/j.intimp.2023.110742}
}
EUVIMED